Evidence map›Paper›PMID 27796538›Full record

ArticleWorld journal of urology2017

Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer.

Katharina Boehm, Paolo Dell'Oglio, Zhe Tian, Umberto Capitanio, Felix K H Chun, Derya Tilki, Axel Haferkamp, Fred Saad, Francesco Montorsi, Markus Graefen and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Radical prostatectomy is associated with favorable outcomes in patients over 80 years old.American journal of clinical and experimental urology · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Impact of comorbidities at diagnosis on prostate cancer treatment and survival.Journal of cancer research and clinical oncology · 2018
    Article
  12. Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Katharina BoehmCancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada. katharina.boehm@unimedizin-mainz.de.
Paolo Dell'OglioCancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.
Zhe TianCancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.
Umberto CapitanioUnit of Urology, Division of Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Felix K H ChunDepartment of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Derya TilkiMartini-Clinic, Prostate Cancer Centre, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Axel HaferkampDepartment of Urology, University Medical Center, Johannes Gutenberg University, Mainz, Germany.
Fred SaadDepartment of Urology, University of Montreal Health Center, Montreal, Canada.
Francesco MontorsiUnit of Urology, Division of Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Markus GraefenMartini-Clinic, Prostate Cancer Centre, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Pierre I KarakiewiczCancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.
Université de Montréal · CAIRCCS Ospedale San Raffaele · ITJohannes Gutenberg University Mainz · DEMartini-Klinik · DEUniversität Hamburg · DEUniversity Medical Center Hamburg-Eppendorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAge and Charlson comorbidity index (CCI) affect life expectancy (LE) and other-cause mortality (OCM) in non-metastatic prostate cancer (nmPCa) patients. We examined their ability to predict OCM in individuals treated with radical prostatectomy (RP), brachytherapy (BT), external beam radiation (EBRT) androgen deprivation (ADT) or observation. We postulated that these variables are not sufficient to explain OCM and LE patterns according to different treatment types. PATIENTS AND

methodsWe relied on the SEER-Medicare database from 1991 to 2009. Overall, 283,125 patients with non-metastatic prostate cancer aged ≥66 years were treated with RP (15.5%), BT (13.9%), EBRT (21.4%), ADT alone (16.3%) or observation (32.8%). Cumulative incidence of OCM and LE was stratified by treatment type and adjusted for age and CCI. Competing risks regression was also used.

resultsOCM rates vary according to treatment, despite age and CCI adjustment. In RP or BT patients, LE exceeds 10 years, regardless of age and CCI. Conversely, a 10-year LE is not reached by patients >74 years treated with observation or ADT. In OCM competing risks regression, age, CCI and treatment type achieved independent predictor status (all p < 0.001).

conclusionIn patients with nmPCa, neither age nor CCI can accurately estimate OCM or LE in excess of 10 years. Primary treatment assignment is a strong determinant of OCM and LE, where RP and BT patients enjoy better OCM and LE rates than observation ADT or EBRT patients. In consequence, better clinical tools are needed to accurately assess OCM and LE in those settings.

Indexed as

Life ExpectancyProstatic NeoplasmsAgedAge FactorsAntineoplastic Agents, HormonalComorbidityHumansMaleMedicareMiddle AgedNeoplasm StagingProstatectomyRadiotherapyRisk AssessmentRisk FactorsSurvival RateAntineoplastic Agents, HormonalCompeting risks analysisElderly patientsLife expectancyMortalityProstate cancerRadical prostatectomy

Identifiers

PMID27796538
OpenAlexW2545851704

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.